Clinical Trial Update: A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms [Phase 3]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 3 study of subcutaneous risankizumab in pediatric participants with moderate-to-severe plaque psori…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2025-05-20